Source: Investigational New Drugs. Unidades: ICB, FMRP, FM
Subjects: FARMACOLOGIA, LEUCEMIA MIELOIDE, INSULINA, ANTINEOPLÁSICOS, PROTEÍNAS QUINASES, CÉLULAS SANGUÍNEAS, PROLIFERAÇÃO CELULAR, APOPTOSE, ONCOGENES
ABNT
RIBEIRO, Renata Scopim; REGO, Eduardo Magalhães; TOGNON, Cristina E.; et al. NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia. Investigational New Drugs, New York, Springer New York LLC, p. 11 , 2021. DOI: 10.1007/s10637-020-01028-8.APA
Ribeiro, R. S., Rego, E. M., Tognon, C. E., Druker, B. J., Traina, F., Machado Neto, J. A., et al. (2021). NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia. Investigational New Drugs, 11 . doi:10.1007/s10637-020-01028-8NLM
Ribeiro RS, Rego EM, Tognon CE, Druker BJ, Traina F, Machado Neto JA, Eide CA, Silva JLC da, Fenerich BA, Fernandes JC, Scheucher PS, Stevens SLS, Campos P de M, Saad STO, Palma L de C, Pontes LL de F, Simões BP. NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia. Investigational New Drugs. 2021 ;11 .Vancouver
Ribeiro RS, Rego EM, Tognon CE, Druker BJ, Traina F, Machado Neto JA, Eide CA, Silva JLC da, Fenerich BA, Fernandes JC, Scheucher PS, Stevens SLS, Campos P de M, Saad STO, Palma L de C, Pontes LL de F, Simões BP. NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia. Investigational New Drugs. 2021 ;11 .